Archived Announcements

NMS Labs Releases New Test To Identify Insomnia Drugs Eszopiclone/Zopiclone And Help Provide Investigative Insights


NMS Labs now offers a test that identifies and provides a quantitative result of Eszopiclone/Zopiclone in blood, urine, serum/plasma or tissue samples.

NMS Labs' new assay can be a valuable resource when you need to know if:

  • An individual's therapeutic levels are on target of if there are potential toxic concentrations
  • An individual has had a drug overdose
  • An individual has been abusing Zopiclone or Eszopiclone

About Eszopiclone/Zopiclone:

Zopliclone was first introduced in 1988 as a novel hypnotic agent used in the treatment of insomnia. It is currently marketed in 85 foreign countries worldwide as Imovane®, but has never been registered in the U.S. The Drug Enforcement Administration (DEA) has listed Zopiclone as a Schedule IV substance due to some evidence that the drug has addictive properties similar to benzodiazepines. Zopiclone is a mixture of two isomers with identical atoms that are arranged differently. Eszopiclone (S-Zopiclone) is one of the two chiral forms and is much more active than the R-Zopiclone isomer. In 2005, Eszopiclone began to be marketed in the U.S. under the trade name Lunesta® for the treatment of insomnia.

About NMS Labs:

NMS Labs is the go-to lab for healthcare providers, medical researchers, and the criminal justice system needing state-of-the-art tests that other labs don’t provide. A national reference laboratory, NMS is unsurpassed in its scope of tests, accuracy of results, scientific expertise, and innovation. NMS Labs is passionate about promoting public health and safety. For more information on NMS Labs please visit

NMS Labs: When you need to know.™

Learn More:

For technical specifications on Eszopiclone/ Zopiclone, see our technical information sheet at or call NMS Labs at 800-522-6671.

« Return to News Listing